Immunoglobulin repletion during blinatumomab therapy does not reduce the rate of secondary hypogammaglobulinemia and associated infectious risk

BACKGROUND: Blinatumomab has demonstrated efficacy in minimal residual disease (MRD) positive and relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) by inciting rapid and sustained B-cell depletion. METHODS: Owing to its effect on B-cells, blinatumomab is associated with a higher rate o...

Descripción completa

Detalles Bibliográficos
Autores principales: Wo, Stephanie, Levavi, Hannah, Mascarenhas, John, Kremyanskaya, Marina, Navada, Shyamala, Bar-Natan, Michal, Kim, Sara S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242831/
https://www.ncbi.nlm.nih.gov/pubmed/35551109
http://dx.doi.org/10.5045/br.2022.2021163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242831/
https://www.ncbi.nlm.nih.gov/pubmed/35551109
http://dx.doi.org/10.5045/br.2022.2021163

Ejemplares similares